|Printable version||E-mail this to a friend|
How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
Antonio Tajani elected new President of the European Parliament18/01/2017 16:20:00
Antonio Tajani (EPP, IT) won Parliament’s presidential election with 351 votes in a final face-off with Gianni Pittella (S&D, IT), who secured 282 votes.
MAR guidelines on commodity derivatives now available in all EU languages18/01/2017 15:05:00
The European Securities and Markets Authority (ESMA) has issued the official translations of its final guidelines on commodity derivatives under the Market Abuse Regulation (MAR).
EU and US publish TTIP state of play assessment18/01/2017 13:20:00
Trade Commissioner Cecilia Malmström and United States Trade Representative Michael Froman have published a joint assessment of the progress made in the negotiations for a Transatlantic Trade and Investment Partnership (TTIP) since negotiations started in July 2013.
Mid-career reviews key to longer and healthier working lives18/01/2017 11:25:00
Eurofound's new report Changing places: Mid-career review and internal mobility shows that timely mid-career reviews can improve an employee's working life, boost their added value to their employer, and help to address Europe's long-term demographic ageing challenge.
Progress in relations between the EU and Switzerland17/01/2017 15:10:00
Following Switzerland's adoption of the Federal Act on Foreign Nationals on 16 December 2016 and the meeting of the EU-Switzerland Joint Committee on 22 December, the Commission welcomes the progress in EU-Swiss relations in several areas.